SM-164

CAS No. 957135-43-2

SM-164( —— )

Catalog No. M22507 CAS No. 957135-43-2

SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains (IC50: 1.39 nM). It acts as an extremely potent antagonist of XIAP. SM-164 binds to XIAP being 300 and 7000-times more potent than its monovalent counterparts and the natural Smac AVPI peptide, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 156 In Stock
5MG 260 In Stock
10MG 399 In Stock
25MG 646 In Stock
50MG 896 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    SM-164
  • Note
    Research use only, not for human use.
  • Brief Description
    SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains (IC50: 1.39 nM). It acts as an extremely potent antagonist of XIAP. SM-164 binds to XIAP being 300 and 7000-times more potent than its monovalent counterparts and the natural Smac AVPI peptide, respectively.
  • Description
    SM-164 binds to XIAP protein containing both the BIR2 and BIR3 domains (IC50: 1.39 nM). It acts as an extremely potent antagonist of XIAP. SM-164 binds to XIAP being 300 and 7000-times more potent than its monovalent counterparts and the natural Smac AVPI peptide, respectively. The binding affinities of SM-164 to XIAP, cIAP-1, and cIAP-2 proteins are determined using fluorescence-polarization based assays. SM-164 concurrently interacts with both BIR domains in XIAP and functions as an ultra-potent antagonist of XIAP in both cell-free functional and cell-based assays. SM-164 targets cellular XIAP and effectively induces apoptosis at concentrations as low as 1 nM in leukemia cancer cells while having minimal toxicity to normal human primary cells at 10,000 nM. SM-164 has a Ki value of 0.56 nM to XIAP protein containing both BIR2 and BIR3 domains. SM-164 has a Ki value of 0.31 nM to a cIAP-1 protein containing both BIR2 and BIR3 domains. SM-164 binds to cIAP-2 BIR3 protein with Ki values of 1.1 nM.SM-164 is highly effective in the inhibition of tumor growth and capable of achieving tumor regression in the MDA-MB-231 xenograft model. SM-164 (1 mg/kg) treatment fully inhibits tumor growth during the treatment. SM-164 (5 mg/kg) treatment reduces the tumor volume from 147±54 mm3 at the beginning of the treatment (day 25) to 54±32 mm3 at the end of the treatment (day 36), a reduction of 65%. The strong antitumor activity by SM-164 is long-lasting and not transient. SM-164 (5 mg/kg) is statistically more effective than Taxotere at the end of the treatment (P<0.01) or when the tumor size in the control group reached 750 mm3 (P<0.02).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    IAP
  • Recptor
    XIAP|cIAP-1|XIAP|cIAP-2|cIAP
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    957135-43-2
  • Formula Weight
    1121.42
  • Molecular Formula
    C62H84N14O6
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:5.2 mg/mL (4.64 mM; Need ultrasonic)
  • SMILES
    [H][C@]12CC[C@H](N1C(=O)[C@H](CCCC2)NC(=O)[C@H](C)NC)C(=O)N[C@H](c1cn(CCCCc2ccc(CCCCn3cc(nn3)[C@@H](NC(=O)[C@@H]3CC[C@]4([H])CCCC[C@H](NC(=O)[C@H](C)NC)C(=O)N34)c3ccccc3)cc2)nn1)c1ccccc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Sun H, et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc. 2007 Dec 12;129(49):15279-94.
molnova catalog
related products
  • MV1

    A small-molecule IAP antagonist that binds to select baculovirus IAP repeat (BIR) domains resulting in dramatic induction of auto-ubiquitination activity and rapid proteasomal degradation of c-IAPs.

  • MX106

    MX106 is a novel potent survivin inhibitor, effectively suppresses MDA-MB-231 cells proliferation with IC50 of 2.2 uM.

  • T-3256336

    A potent, selective, orally available IAP antagonist with IC50 of 1.3, 2.2 and 200 nM for cIAP-1, cIAP-2 and XIAP, respectively.